Combined therapy with luteinizing hormone releasing hormone agonist (LHRHa) and growth hormone (GH) in central precocious puberty.

Luteinizing Hormone Releasing Hormone analogues (LHRHa) are considered the treatment of choice in central precocious puberty (CPP). Final height after therapy is usually higher than the predicted one before treatment, but about 60% of patients do not reach their genetic target. The association of Growth Hormone (GH) with LHRHa could be useful in a subgroup of children with CPP and low growth velocity in order to obtain a higher final height with a complete expression of genetic potential.

One year experience at the Emergency Unit of the Children's Hospital of Parma.

The objective of the study was to analyse the activity of the Paediatric Emergency Unit (PEU) of the Children's Hospital in Parma, Italy, in the first year of its functioning. To this aim, the child's chronological age, place of origin (town or province), ethnic group, cause of consultation, time and date of admission, diagnosis and final destination were retrospectively collected from the clinical notes of all children who attended PEU from 1st. 10.